Article Text

Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
  1. Isabel Comino1,
  2. Ana Real1,
  3. Laura de Lorenzo1,2,
  4. Hugh Cornell3,
  5. Miguel Ángel López-Casado4,
  6. Francisco Barro5,
  7. Pedro Lorite6,
  8. Ma Isabel Torres6,
  9. Ángel Cebolla7,
  10. Carolina Sousa1
  1. 1Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain
  2. 2Centro Nacional de Biotecnología (CNB-CSIC), Departamento de Genética Molecular de Plantas, Cantoblanco, Madrid, Spain
  3. 3School of Applied Sciences, RMIT University, Melbourne, Australia
  4. 4Hospital Virgen de las Nieves, Granada, Spain
  5. 5Instituto de Agricultura Sostenible (CSIC), Alameda del Obispo, Córdoba, Spain
  6. 6Departamento de Biología Experimental, Campus Universitario Las Lagunillas, Jaén, Spain
  7. 7Biomedal, Sevilla, Spain
  1. Correspondence to Professor Carolina Sousa, Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, C/Profesor García González, no. 2, Sevilla 41012, Spain; csoumar{at}


Background and aims Coeliac disease (CD) is triggered by an abnormal reaction to gluten. Peptides resulting from partially digested gluten of wheat, barley or rye cause inflammation of the small intestinal mucosa. Previous contradictory studies suggest that oats may trigger the abnormal immunological response in patients with CD. Monoclonal antibodies (moAbs) against the main immunotoxic 33-mer peptide (A1 and G12) react strongly against wheat, barley and rye but have less reactivity against oats. The stated aim of this study is to test whether this observed reactivity could be related to the potential toxicity of oats for patients with CD.

Methods In the present study, different oat varieties, controlled for their purity and by their distinct protein pattern, were used to examine differences in moAb G12 recognition by ELISA and western blot. Immunogenicity of oat varieties was determined by 33-mer concentration, T cell proliferation and interferon γ production.

Results Three groups of oat cultivars reacting differently against moAb G12 could be distinguished: a group with considerable affinity, a group showing slight reactivity and a third with no detectable reactivity. The immunogenicity of the three types of oats as well as that of a positive and negative control was determined with isolated peripheral blood mononuclear T cells from patients with CD by measurement of cell proliferation and interferon γ release. A direct correlation of the reactivity with G12 and the immunogenicity of the different prolamins was observed.

Conclusions The results showed that the reactivity of the moAb G12 is proportional to the potential immunotoxicity of the cereal cultivar. These differences may explain the different clinical responses observed in patients suffering from CD and open up a means to identify immunologically safe oat cultivars, which could be used to enrich a gluten-free diet.

  • Coeliac disease
  • oats
  • moAb
  • T cells

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials


  • Funding This work was supported by Asociación de Celíacos de Madrid (to SC) by grants PET2008_0055 from VI Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (Ministerio de Ciencia e Innovación), IAB (Instituto Andaluz de Biotecnología) (to SC) and by AGR2009-4966M (Proyecto de Excelencia, Junta de Andalucía) (to TM). Biomedal thanks Corporación Tecnológica de Andalucía and Agencia IDEA for co-founding this study (to CA).

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Hospital Virgen de las Nieves, Granada, Spain.

  • Provenance and peer review Not commissioned; externally peer reviewed.